Protego Biopharma closed an oversubscribed $130 million Series B to advance PROT‑001, its first‑in‑class oral therapy for AL (light chain) amyloidosis, into a pivotal study. The financing draws participation from strategic life‑science investors and aims to fund a registrational program and scale manufacturing. Protego describes PROT‑001 as a small‑molecule stabilizer that targets misfolded immunoglobulin light chains; the company positions the approach as a potential alternative to antibody‑based programs that failed pivotal tests earlier this year. Management said the cash runway will support clinical and CMC milestones ahead of a planned pivotal start next year, and the round signals investor appetite for rare‑disease, mechanistically differentiated oral programs.